Date: November 6, 2025
Venue: Kyoto International Conference Center
Organizer: Scarecrow Incorporated and Pet Sun Limited
Our relationship with Thailand has been ongoing for approximately 15 years.
The first conference was held approximately two years ago at the Excel Tokyu Hotel in Shibuya Mark City, Tokyo.
https://pet-medical.info/?p=373
This conference features presentations with Japanese and Thai veterinarians, professors, and specialists, focusing on the clinical effects of our developed products, such as Pinfenon-S and LPS Dr Super

From Thailand, we were honored to welcome professors and the president of the Veterinary Association from leading institutions comparable to the University of Tokyo and Kyoto University.
These include Mahidol University, Chulalongkorn University, Kasetsart University, and Prince of Songkla University.


Regarding Pinfenon-S, a Japanese patent has been granted for its use as an ANP-reducing agent and therapeutic/preventive product for mitral valve insufficiency.
Through the PCT route, we have already filed patent applications in Taiwan, South Korea, Vietnam, and Thailand.
We aim to present to the world a method to delay the age at which dogs and cats develop MR, offering an approach that reduces dependence on conventional medications.

For earthworm protein, Waki Pharmaceutical Co., Ltd.—an organization with 140 years of history—presented academic findings on its thrombolytic effects.


For Taheebo, a practitioner from the Kansai region, presented clinical insights on its anti-tumor effects.

As international validation, we received clear and compelling data from a professor at Chulalongkorn University in Thailand, and a related academic paper is scheduled to be published in Thailand next year.

Our company earns revenue through animal hospitals that care for dogs and cats around the world. Wishing to align ourselves, even slightly, with the compassion of Luangta Maha Bua, who is both a revered Thai spiritual leader and monk, we renewed our determination to express our gratitude by contributing to global donations.
Written by
Hiroshi Okawa
President & CEO, Scarecrow Inc.













